ArticleInflammopharmacology2026
Hydroxytyrosol-encapsulated solid lipid nanoparticles mitigate induced arthritis via modulating the cytokines and MMP-13 expression and downregulating oxidative stress in rats.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a chronic inflammatory disease characterized by progressive degeneration of joints and systemic complications. This study aimed at the development and evaluation of hydroxytyrosol-loaded solid lipid nanoparticles as a promising therapeutic approach against FCA-induced arthritis in rats. Hydroxytyrosol-loaded nanoparticles were prepared using stearic and lauric acids with Tween 80, showing a mean particle size of 109.7 nm, a zeta potential of − 26.0 mV, and a high encapsulation efficiency (96.5%). In vitro antioxidant and anti-inflammatory activities were performed by total phenolic and flavonoid content, DPPH radical scavenging assay, hemolytic assay, and protein denaturation assay. The developed formulation was subjected to an in vivo study using 35 rats divided into seven groups. HT-NPs at a dose of 40 mg/kg showed a significant reduction in arthritic score (0.78 ± 0.08) when compared to arthritic control (3.78 ± 0.08) and markedly decreased paw swelling (4.68 ± 0.13 vs. 5.92 ± 0.26). The treatment restored the oxidative balance by increased SOD (9.0 ± 0.2 U/mL) and CAT (66 ± 1.0 U/mL) and reduced MDA levels to 2.7 ± 0.10 nmol/mL. Further, HT-NPs treatment showed downregulation of pro-inflammatory and tissue-degrading genes such as TNF-α (1.30 ± 0.07 vs. 5.90 ± 0.16), IL-1β (1.50 ± 0.07 vs. 7.00 ± 0.16), and MMP-13 (2.12 ± 0.02 vs. 5.97 ± 0.08) while upregulating anti-inflammatory cytokines IL-10 and IL-4. The therapeutic potential of HT-NPs at high doses was comparable to methotrexate. These findings suggest that nanoencapsulation significantly enhances hydroxytyrosol’s therapeutic potential and thus support HT-NPs as a promising natural and safer alternative in the management of RA.
Indexed as
Identifiers
41784929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.